PRIMARY STUDY

The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers

Key Findings:  THCv (CB1 neutral antagonist) may provide a therapeutic treatment option for obesity, where functional connectivity is altered in certain regions of the brain.

Type of Study:  Double Blind Clinical Trial

Study Sample Size:  20

Study Result:  Positive

Study Location(s):  United Kingdom

Year of Pub:  2016


Cannabinoids Studied:  Tetrahydrocannabivarin (THCV)

Phytocannabinoid Source:  Unspecified

Receptors Studied:  CB1

Dosage: THCv (10mg/day)

Route of Administration:  Oral (Ingestion)



Link to study